

Out. number: 194-00-187/05.12.2025

Notification on the terms and conditions for distribution of the dividend voted at the Extraordinary General Meeting of Shareholders of "Sopharma" AD held on December 05, 2025

Sofia, Bulgaria, December 05, 2025 – In accordance with the requirements of art. 115c, para. 4 of LPOS **"Sopharma" AD** (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the EGM of "Sopharma" AD that took place on December 05, 2025 regarding the type and amount of the voted dividend for the 6 months of 2025, the terms and conditions for its payment:

The General Meeting of Shareholders voted against the proposal of the Board of Directors and approved a proposal from a shareholder to distribute a gross dividend to shareholders in the amount of BGN 0.08801 /EUR 0.045 (8.801 stotinki /4.5 eurocents) per share.

The right to receive dividends is granted to persons registered in the register of „Central Depository“ AD as shareholders on the 14th day after the day of the General Meeting at which the 6-month financial report for 2025 was adopted and a decision was made to pay a dividend, namely 19 December 2025 (dividend record date); respectively, ex-dividend date – 18 December 2025; dividend payment date – 2 February 2026.

In accordance with the Regulations of "Central Depository" AD, the dividend will be paid as follows: for shareholders with open client accounts with investment intermediaries - through the respective investment intermediary; for shareholders without accounts with investment intermediaries - through the branches of "Eurobank Bulgaria" AD (Post Bank) in the country.

We draw the attention of all foreign shareholders who wish to provide original documents for avoiding double taxation to do so no later than 16 January 2026 at the address: Sofia 1756, 5 "Lachezar Stanchev" Str., Tower A, floor 11, for the attention of the Investor Relations Department (contacts for additional information ir@sopharma.bg / +359 2 8134 319).

Pelagia Viatcheva

Investor Relations Director

Information about the company

“Sopharma” AD

More than 90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate sustainability practices.

The company carries out production and trade of medicinal substances and dosage forms; scientific research and engineering-implementation activities in the field of phytochemistry, chemistry and pharmacy, production of medical devices and cosmetic products, including – plasters, dressing products, medical cosmetics and concentrates for hemodialysis.

Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products’ manufacturing, hospital supplies, medicinal products’ distribution, retail and many others.